Core Viewpoint - The company emphasizes the importance of innovation in the medical service industry, particularly in response to changes in medical insurance policies that affect profitability and operational efficiency [1][2]. Group 1: Company Operations - The company has experienced a decline in medical service gross margins due to adjustments in medical insurance settlement policies, despite an increase in outpatient and inpatient volumes [2]. - The company operates four hospitals: Jianhua Hospital, Kanghua Hospital, Futian Hospital, and Mingzhu Hospital, which are actively making adjustments to cope with market changes [2]. - The company is focusing on enhancing the quality and efficiency of its hospitals while investing in emerging medical technologies such as brain-computer interface (BCI) and AI medical models [2][4]. Group 2: AI Medical Model Development - The AI medical model developed by the company's affiliate, Quanzhen Medical, has demonstrated capabilities in providing diagnostic suggestions and generating medical records, significantly improving doctor efficiency and service quality [3]. - In 2024, Quanzhen Medical anticipates generating revenue of 4.4 million yuan from its AI medical model, with a target of 40 million yuan in 2025 [3]. - The company plans to expand its partnerships with hospitals, aiming to increase the number of collaborations from approximately 60 to 160 in the near future [3]. Group 3: Brain-Computer Interface (BCI) Project - The BCI project has developed a product line that includes systems for rehabilitation training and neuro-signal acquisition, with clinical trials already underway in several hospitals [4]. - The BCI products are expected to complete regulatory registration by mid-2026, with consumer products entering mass production and anticipated market launch in 2025 [4]. Group 4: Future Development Strategy - The company aims to enhance hospital operational capabilities and efficiency while actively exploring the commercialization of advanced medical technologies [5]. - The focus will be on capital operations that align with the company's strategic direction and investment value, leveraging technological advancements to improve the medical service industry [5].

Group 1: Company Overview and Performance - The company focuses on comprehensive medical services, primarily relying on local health insurance bureaus for revenue settlement [4] - Despite an increase in outpatient and inpatient volumes in 2024, the company's operating performance has declined due to adjustments in health insurance settlement policies, leading to reduced service charges and lower gross margins [4] - The company has invested in innovative projects such as brain-computer interfaces (BCI) and AI medical models to enhance traditional medical services [4] Group 2: AI Medical Model Development - The AI medical model currently collaborates with approximately 60 hospitals in 2024, with an expected increase of about 100 hospitals in 2025 [6] - Projected revenue for the AI medical model is estimated at 4.4 million in 2024 and aims for 40 million in 2025 [6] - The AI model has shown significant cost reduction and efficiency improvement in hospitals, particularly through features like in-clinic dictation and inpatient dictation [6] Group 3: BCI Product Development - The BCI product assists stroke patients in regaining control over their upper limb movements, enabling basic daily activities [7] - The BCI product can operate for approximately 6 hours on a single charge, with a replaceable battery [8] - The BCI product is undergoing multi-center clinical trials and is expected to complete registration for medical device classification by mid-2026 [8] Group 4: Market Impact and Financial Projections - The BCI product is anticipated to significantly reduce rehabilitation costs for patients, allowing families to save between 40,000 to 60,000 annually by replacing full-time caregivers with part-time help [10] - The pricing strategy for the BCI product is based on the value it provides to stroke patients, with specific pricing details to be announced upon launch [10]

中银创新医疗混合A股票持仓前十占比合计70.44%，分别为：科伦博泰生（9.77%）、恒瑞医药 （9.39%）、信达生物（8.54%）、康方生物（8.24%）、康诺亚-B（6.59%）、新诺威（6.27%）、百济 神州-U（6.02%）、百利天恒（5.89%）、和黄医药（5.16%）、翰森制药（4.57%）。 金融界2025年4月23日消息，中银创新医疗混合A(007718) 最新净值1.6795元，下跌1.12%。该基金近1个 月收益率18.94%，同类排名9|4629；近3个月收益率42.92%，同类排名15|4571；今年来收益率39.57%， 同类排名21|4554。 简历显示：郑宁先生:中国,研究生、硕士。曾任泰康资产管理有限责任公司股票研究经理、高级股票研 究经理;中庚基金管理有限公司研究员、高级研究员(医药组组长)。2022年加入中银基金管理有限公司。 2022年7月1日担任中银创新医疗混合型证券投资基金基金经理。2022年10月13日担任中银医疗保健灵活 配置混合型证券投资基金基金经理。2023年2月28日任中银大健康股票型证券投资基金基金经理。 来源：金融界 公开资料显示，中银创新医疗混合A ...

证券代码：002173 证券简称：创新医疗 公告编号：2025-021 创新医疗管理股份有限公司 关于持股 5%以上股东权益变动触及 1%的提示性公告 股东上海洸焕科技有限公司保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 | 股份种类（A 股、B 股等） | 减持股数（万股） 减持比例（%） | | | --- | --- | --- | | A 股 | 470 1.0651% | | | 合 计 | 470 1.0651% | | | 本次权益变动方式 | 通过证券交易所的集中交易 √ | | | | 通过证券交易所的大宗交易 √ | | | | 其他 □（请注明） | | | 3．本次变动前后，投资者及其一致行动人拥有上市公司权益的股份情况 | | | | 股份性质 | 本次变动前持有股份 本次变动后持有股份 | | | | 占总股本比 占总股本比 股数(万股) 股数(万股) | | | | 例(%) 例(%) | | | 合计持有股份 | 3,372.0222 7.6414% 2,902.0222 6.5763% | | | 其中：无限售条件股份 | 3,372.0 ...

■ ■ ■ 0 0 2173 ■ ■ ■ 5% ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ 2025 每4年13 ■ 2025 每4年18 ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ 1.0 © ■ ■ ■ ■ ■ ■ 1.06 5 1% ■ ...

Group 1 - The core point of the news is the performance of the Zhongyin Innovation Medical Mixed A fund, which has shown significant growth in its net value and returns over various time frames [1] - As of April 21, 2025, the latest net value of Zhongyin Innovation Medical Mixed A is 1.6127 yuan, reflecting a growth of 2.27% [1] - The fund's one-month return is 14.21%, ranking 9th out of 4672 similar funds; the three-month return is 36.72%, ranking 18th out of 4599; and the year-to-date return is 34.02%, ranking 36th out of 4590 [1] Group 2 - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 70.60%, with significant positions in companies such as Heng Rui Pharmaceutical (9.81%), Innovent Biologics (8.55%), and others [1] - The fund was established on November 13, 2019, and as of December 31, 2024, it has a total scale of 2.02 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry since 2022 [2]

公开信息显示，现任基金经理吴兴武先生:中国籍,理学硕士,持有中国证券投资基金业从业证书,曾任摩 根士丹利华鑫基金管理有限公司研究员,广发基金管理有限公司研究发展部、权益投资一部研究员、广 发多元新兴股票型证券投资基金基金经理(自2017年4月25日至2019年4月16日)、广发核心精选混合型证 券投资基金基金经理(自2015年2月17日至2020年2月10日)、广发鑫瑞混合型证券投资基金(LOF)基金经 理(自2019年4月16日至2020年7月29日)、广发再融资主题灵活配置混合型证券投资基金(LOF)基金经理 (自2019年4月16日至2020年7月31日)。现任广发轮动配置混合型证券投资基金基金经理(自2015年2月12 日起任职)、广发医疗保健股票型证券投资基金基金经理(自2018年10月16日起任职)、广发医药健康混合 型证券投资基金基金经理(自2020年10月21日起任职)、广发创新医疗两年持有期混合型证券投资基金基 金经理(自2021年3月19日起任职)。2022年11月4日起任广发竞争优势灵活配置混合型证券投资基金基金 经理。曾任广发主题领先灵活配置混合型证券投资基金基金经理。 截止2024年 ...

Core Viewpoint - The recent performance of the Zhongyin Innovation Medical Mixed A fund shows a decline in net value but strong returns over various time frames, indicating potential resilience in the healthcare investment sector [1]. Fund Performance Summary - The latest net value of Zhongyin Innovation Medical Mixed A is 1.5786 yuan, down by 2.81% - The fund's one-month return is 13.30%, ranking 7 out of 4623 in its category - The three-month return stands at 38.74%, ranking 14 out of 4566 - Year-to-date return is 31.19%, ranking 24 out of 4559 [1]. Holdings Summary - The top ten stock holdings of Zhongyin Innovation Medical Mixed A account for a total of 70.60%, with the following key positions: - Heng Rui Pharmaceutical: 9.81% - Xinda Bio: 8.55% - Huaneng Pharmaceutical: 8.41% - Kangfang Biotech: 8.35% - Kangnuo Ya-B: 8.32% - Kelun Botai: 7.87% - BeiGene-U: 6.24% - Rongchang Bio: 5.96% - Hansoh Pharmaceutical: 3.98% - Xin Nuo Wei: 3.11% [1]. Fund Manager Background - Zheng Ning, the fund manager, has a master's degree and extensive experience in the investment sector, having previously worked at Taikang Asset Management and Zhonggeng Fund Management - Zheng joined Zhongyin Fund Management in 2022 and has managed multiple funds since then, including the Zhongyin Innovation Medical Mixed Fund [2].

证券代码：002173 证券简称：创新医疗 公告编号：2025-020 创新医疗管理股份有限公司 关于召开 2024 年度现场业绩说明会的通知 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚假 记载、误导性陈述或者重大遗漏。 创新医疗管理股份有限公司（以下简称"创新医疗"或"公司"）已于 2025 年 4 月 12 日在巨潮资讯网（www.cninfo.com.cn）上披露了《2024 年年度报告》 等相关公告。为做好上市公司投资者关系管理工作，同时便于广大投资者更全面 深入地了解公司 2024 年年度经营情况，公司将举行 2024 年度现场业绩说明会， 就投资者关心的问题进行交流。 一、本次业绩说明会召开的时间、地点 （一）会议召开时间：2025 年 4 月 23 日（星期三）15:00—17:00 （二）会议召开地点：浙江省杭州市上城区城星路 98 号迪凯城星国际 A 座 34 楼创新医疗杭州分公司会议室 二、投资者参加方式 三、公司参会人员 公司董事长陈海军先生、董事游向东先生、总裁马建建先生、董事会秘书郭 1 / 2 立丹女士。同时，公司还邀请了参股企业全诊医学董事长薛翀先生参加本次 ...

医药健康是本届科博会聚焦的前沿领域之一。据了解，北京市将医药健康产业作为创新发展的"双发动 机"之一，滚动实施了3个产业发展"三年行动计划"。2024年产业规模达到1.06万亿元，同比增长8.7%。 北京出台了促进创新医药发展的"32条"措施等，率先实现了"药品补充申请审评时限从200天压缩至60 天""药品临床试验审批从60天压缩至30天"，临床试验的启动用时压缩7.7周。实施罕见病药品的"白名 单"制度，建立了临床急需进口药械的审批绿色通道，进口货值超过1500亿元，位居全国首位。记者了 解到，今年还将持续推出新的"32条"改革举措。 依托"两区"建设和中关村先行先试的政策，北京推出数据出境绿色通道、建设创新药械的出海平台，吸 引一批外资企业加大在京布局，去年辉瑞、默沙东、礼来等8家知名药企在京新设创新主体。 骨科手术机器人操作关节置换手术仅需30分钟 第二十七届北京国际科技博览会（北京科博会）将于5月8日至11日在国家会议中心举办。4月14日，记 者从北京市贸促会了解到，本届科博会展览总面积约5万平方米，设置信息科技、智能制造、医药健 康、绿色双碳、数字经济和区域创新等六大展区，同期还将举办2025北京 ...